These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 24336156

  • 21. Molecular characterization of a rare case of high-grade B-cell lymphoma with MYC, BCL2, BCL6, and CCND1 rearrangements.
    Monika F, Sabri A, Cantu D, Vail E, Siref A.
    J Hematop; 2024 Sep; 17(3):155-161. PubMed ID: 38914869
    [Abstract] [Full Text] [Related]

  • 22. Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
    Ennishi D, Jiang A, Boyle M, Collinge B, Grande BM, Ben-Neriah S, Rushton C, Tang J, Thomas N, Slack GW, Farinha P, Takata K, Miyata-Takata T, Craig J, Mottok A, Meissner B, Saberi S, Bashashati A, Villa D, Savage KJ, Sehn LH, Kridel R, Mungall AJ, Marra MA, Shah SP, Steidl C, Connors JM, Gascoyne RD, Morin RD, Scott DW.
    J Clin Oncol; 2019 Jan 20; 37(3):190-201. PubMed ID: 30523716
    [Abstract] [Full Text] [Related]

  • 23. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
    Molina TJ, Canioni D, Copie-Bergman C, Recher C, Brière J, Haioun C, Berger F, Fermé C, Copin MC, Casasnovas O, Thieblemont C, Petrella T, Leroy K, Salles G, Fabiani B, Morschauser F, Mounier N, Coiffier B, Jardin F, Gaulard P, Jais JP, Tilly H.
    J Clin Oncol; 2014 Dec 10; 32(35):3996-4003. PubMed ID: 25385729
    [Abstract] [Full Text] [Related]

  • 24. Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.
    Scott DW, Mottok A, Ennishi D, Wright GW, Farinha P, Ben-Neriah S, Kridel R, Barry GS, Hother C, Abrisqueta P, Boyle M, Meissner B, Telenius A, Savage KJ, Sehn LH, Slack GW, Steidl C, Staudt LM, Connors JM, Rimsza LM, Gascoyne RD.
    J Clin Oncol; 2015 Sep 10; 33(26):2848-56. PubMed ID: 26240231
    [Abstract] [Full Text] [Related]

  • 25. p53 expression in large B-cell lymphomas with MYC extra copies and CD99 expression in large B-cell lymphomas in relation to MYC status.
    Richardson AI, Zhang D, Woodroof J, Cui W.
    Hum Pathol; 2019 Apr 10; 86():21-31. PubMed ID: 30496802
    [Abstract] [Full Text] [Related]

  • 26. BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial.
    Petrella T, Copie-Bergman C, Brière J, Delarue R, Jardin F, Ruminy P, Thieblemont C, Figeac M, Canioni D, Feugier P, Fabiani B, Leroy K, Parrens M, André M, Haioun C, Salles GA, Gaulard P, Tilly H, Jais JP, Molina TJ.
    Ann Oncol; 2017 May 01; 28(5):1042-1049. PubMed ID: 28327893
    [Abstract] [Full Text] [Related]

  • 27. Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.
    Landsburg DJ, Falkiewicz MK, Petrich AM, Chu BA, Behdad A, Li S, Medeiros LJ, Cassaday RD, Reddy NM, Bast MA, Vose JM, Kruczek KR, Smith SE, Patel P, Hernandez-Ilizaliturri F, Karmali R, Rajguru S, Yang DT, Maly JJ, Blum KA, Zhao W, Vanslambrouck C, Nabhan C.
    Br J Haematol; 2016 Nov 01; 175(4):631-640. PubMed ID: 27469075
    [Abstract] [Full Text] [Related]

  • 28. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.
    Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, Liu WM, Visco C, Li Y, Miranda RN, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Zhao X, van Krieken JH, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Zhou F, Slack GW, Gascoyne RD, Tu M, Variakojis D, Chen W, Go RS, Piris MA, Møller MB, Medeiros LJ, Young KH.
    Blood; 2013 May 16; 121(20):4021-31; quiz 4250. PubMed ID: 23449635
    [Abstract] [Full Text] [Related]

  • 29. P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma.
    Wang XJ, L Jeffrey Medeiros, Bueso-Ramos CE, Tang G, Wang S, Oki Y, Desai P, Khoury JD, Miranda RN, Tang Z, Reddy N, Li S.
    Mod Pathol; 2017 Feb 16; 30(2):194-203. PubMed ID: 27739436
    [Abstract] [Full Text] [Related]

  • 30. Primary extranodal diffuse large B-cell lymphomas: Many sites, many entities? Clinico-pathological, immunohistochemical and cytogenetic study of 106 cases.
    Magnoli F, Bernasconi B, Vivian L, Proserpio I, Pinotti G, Campiotti L, Mazzucchelli L, Sessa F, Tibiletti MG, Uccella S.
    Cancer Genet; 2018 Dec 16; 228-229():28-40. PubMed ID: 30553470
    [Abstract] [Full Text] [Related]

  • 31. Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.
    Rosenwald A, Bens S, Advani R, Barrans S, Copie-Bergman C, Elsensohn MH, Natkunam Y, Calaminici M, Sander B, Baia M, Smith A, Painter D, Pham L, Zhao S, Ziepert M, Jordanova ES, Molina TJ, Kersten MJ, Kimby E, Klapper W, Raemaekers J, Schmitz N, Jardin F, Stevens WBC, Hoster E, Hagenbeek A, Gribben JG, Siebert R, Gascoyne RD, Scott DW, Gaulard P, Salles G, Burton C, de Jong D, Sehn LH, Maucort-Boulch D.
    J Clin Oncol; 2019 Dec 10; 37(35):3359-3368. PubMed ID: 31498031
    [Abstract] [Full Text] [Related]

  • 32. MYC rearrangement and MYC/BCL2 double expression but not cell-of-origin predict prognosis in R-CHOP treated diffuse large B-cell lymphoma.
    Xu J, Liu JL, Medeiros LJ, Huang W, Khoury JD, McDonnell TJ, Tang G, Schlette E, Yin CC, Bueso-Ramos CE, Lin P, Li S.
    Eur J Haematol; 2020 Apr 10; 104(4):336-343. PubMed ID: 31944390
    [Abstract] [Full Text] [Related]

  • 33. BCL2 super-expressor diffuse large B-cell lymphoma: a distinct subgroup associated with poor prognosis.
    Roh J, Cho H, Pak HK, Lee YS, Lee SW, Ryu JS, Chae EJ, Kim KW, Huh J, Choi YS, Jeong SH, Suh C, Yoon DH, Park CS.
    Mod Pathol; 2022 Apr 10; 35(4):480-488. PubMed ID: 34764434
    [Abstract] [Full Text] [Related]

  • 34. Endoscopic appearance of AIDS-related gastrointestinal lymphoma with c-MYC rearrangements: case report and literature review.
    Tanaka S, Nagata N, Mine S, Igari T, Kobayashi T, Sugihara J, Honda H, Teruya K, Kikuchi Y, Oka S, Uemura N.
    World J Gastroenterol; 2013 Aug 07; 19(29):4827-31. PubMed ID: 23922484
    [Abstract] [Full Text] [Related]

  • 35. Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.
    Nowakowski GS, Blum KA, Kahl BS, Friedberg JW, Baizer L, Little RF, Maloney DG, Sehn LH, Williams ME, Wilson WH, Leonard JP, Smith SM.
    J Natl Cancer Inst; 2016 Dec 07; 108(12):. PubMed ID: 27986884
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Dual expression of MYC and BCL2 proteins predicts worse outcomes in diffuse large B-cell lymphoma.
    Clark Schneider KM, Banks PM, Collie AM, Lanigan CP, Manilich E, Durkin LM, Hill BT, Hsi ED.
    Leuk Lymphoma; 2016 Jul 07; 57(7):1640-8. PubMed ID: 26421520
    [Abstract] [Full Text] [Related]

  • 38. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.
    Perry AM, Alvarado-Bernal Y, Laurini JA, Smith LM, Slack GW, Tan KL, Sehn LH, Fu K, Aoun P, Greiner TC, Chan WC, Bierman PJ, Bociek RG, Armitage JO, Vose JM, Gascoyne RD, Weisenburger DD.
    Br J Haematol; 2014 May 07; 165(3):382-91. PubMed ID: 24506200
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
    Xu-Monette ZY, Dabaja BS, Wang X, Tu M, Manyam GC, Tzankov A, Xia Y, Zhang L, Sun R, Visco C, Dybkaer K, Yin L, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Zhao X, Winter JN, Piris MA, McDonnell TJ, Miranda RN, Li Y, Medeiros LJ, Young KH.
    Mod Pathol; 2015 Dec 07; 28(12):1555-73. PubMed ID: 26541272
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.